GlaxoSmithKline, Siena, Italy
https://www.gsk.com/en-gb/responsibility/inside-the-gvgh/

GSK iNTS-TCV
VACCINE
Prevention of iNTS and typhoid fever

Invasive nontyphoidal salmonellosis (iNTS) is an under-recognized highly invasive disease caused mainly by Salmonella enterica serovars Enteritidis and Typhimurium and almost exclusively in resource limited communities of sub-Saharan Africa. The GSK Vaccines Institute for Global Health (GVGH) is developing a new trivalent Salmonella vaccine against iNTS and typhoid fever. An iNTS-typhoid conjugate vaccine (TCV) is needed for sub-Saharan Africa to impact disease burden in very young children and contribute to reduced antibiotic consumption. In this region, there are more than 480,000 cases of iNTS annually with around 70,000 deaths while the burden of Salmonella enterica serovar Typhi is 1.3 million cases and 20,000 deaths/year. Moreover, Salmonellae bacteria carry multiple antimicrobial resistance (AMR) markers and show reduced sensitivity to fluoroquinolones in sub-Saharan Africa. By using GMMA-technology for the vaccine production, the combination of two assets aims to deliver an affordable and sustainable Salmonella vaccine to populations at risk to help protect against both iNTS disease and typhoid fever.

Current Development Stage: Phase I

CARB-X Investment: Initial investment of up to $2.2m, with potential option payments up to $4.0m.

Initial CARB-X Investment Date: October 1, 2020